上海百心安生物技术有限公司(简称“百心安-B”)宣布,其自主研发的Iberis肾动脉去交感神经消融(RDN)系统已正式在泰国完成注册。这一里程碑标志着该创新医疗器械成功迈入东南亚市场,为当地高血压患者提供了全新的治疗方案。
上海百心安生物技术有限公司(简称“百心安-B”)宣布,其自主研发的Iberis肾动脉去交感神经消融(RDN)系统已正式在泰国完成注册。这一里程碑标志着该创新医疗器械成功迈入东南亚市场,为当地高血压患者提供了全新的治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.